This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Oncology Practice Rounds: Harnessing the Power of the Human Immune System to Treat Cancer

Oncology Practice Rounds: Harnessing the Power of the Human Immune System to Treat Cancer

Format

Roundtable

Time to Complete

1.50 hours

Released

August 27, 2018

Expires

August 27, 2019
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM
1.50 / CNE Contact Hours
1.50 / CE for Pharmacists (0.15 CEUs)

Accredited Providers

Presented by the Johns Hopkins University School of Medicine, the Institute for Johns Hopkins Nursing, and the University of Tennessee College of Pharmacy.

Commercial Supporter

Supported by an educational grant from Bristol-Myers Squibb Company.

Program Description

Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized treatment and survival outcomes across a diverse spectrum of solid and hematological malignancies. These paradigm-shifting agents display unique mechanisms of action, response patterns, and safety profiles, all of which differ greatly from more conventional chemotherapy and targeted therapies. As a result, implementing checkpoint inhibitors in clinical practice requires healthcare practitioners to adopt specialized administration, efficacy assessment, and immunemediated adverse reactions (imARs) management strategies. Furthermore, appropriate patient counseling and education remains critical to promote prompt recognition of imARs. This archived educational session will present the most up-to-date evidence on immunotherapy treatment options, cover a wide range of checkpoint inhibitor indications, and discuss clinically relevant strategies to effectively utilize these agents in practice.

Intended Audience

This activity is intended for physicians, pharmacists, nurses, nurse practitioners, and physician assistants who work in oncology-hematology settings. No prerequisites required.

Educational Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • DESCRIBE immune checkpoint blocking drugs, their anti-tumor activity, and their unique mechanisms of action.
  • SUMMARIZE appropriate patient safety assessments before, during and after administration of immune checkpoint blockade therapy.
  • DESCRIBE effective management of immune-mediated adverse reactions (IMARs).
The Johns Hopkins University School of Medicine, the Institute for Johns Hopkins Nursing, and the University of Tennessee College of Pharmacy take responsibility for the content, quality, and scientific integrity of this CME/CNE/CPE activity.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM .   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.50

Type

CNE Contact Hour(s)

Accreditation Statement

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

This 1.50 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until August 15, 2019.

Credit

1.50

Type

CE for Pharmacists

Accreditation Statement

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.50 enduring contact hours of credit (0.15 CEUs).

Designation Statement

Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) studying the educational activity; 3) evaluating the activity; and 4) completing the self-assessment instrument with a score of at least 70%. A statement of CE credit will be generated following successful completion of the educational activity. UAN: 0064-9999-18-202-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER

Pharmacists or pharmacy technicians with questions regarding their CORRECT NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service.

To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their month and day of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

GRIEVANCE POLICY

A participant, provider, faculty member or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by the UTCOP may contact the Associate Dean for Continuing Education in writing at gfarr@utk.edu. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.

FEE INFORMATION

There is no fee for this educational activity.

AMERICANS WITH DISABILITIES ACT (ADA)

The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing fully comply with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

Policy on Speaker and Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.

As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.

Full Disclosure Policy Affecting CME Activities

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed disclosure of the existence of financial relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.

The following relationships have been reported for this activity:

Planner Disclosures

Ms. Brothers reports receiving honorarium for and serving as a senior research nurse for an unrestricted grant for CME/CNE discussion studies concerning immune-mediated adverse events (nonbranded) for Bristol-Myers Squibb Company.

Dr. Lipson reports serving as a consultant and a principal investigator for Bristol-Myers Squibb Company; serving as a principal investigator for Merck & Co Inc; and serving as a consultant for Array BioPharma Inc.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

STEERING COMMITTEE

Trish Brothers, BSN, RN, OCN
Senior Research Nurse
Melanoma and Cancer Immunology Programs
Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan J. Lipson, MD
Assistant Professor of Medical Oncology
Melanoma and Cancer Immunology Programs
Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Non-Endorsement of Products

The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

Off-Label Product Discussion

In accordance with ACPE Criteria for Quality, the audience is advised that presenters in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the audience of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

Clinical and Therapeutic Updates

The following approvals were granted subsequent to activity posting:

  • On August 16, 2018, nivolumab was granted accelerated approval in treating patients with metastatic small cell lung cancer with progression after platinum-based chemotherapy and at least 1 other line of therapy.

Disclaimer

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

Confidentiality Disclaimer for CME Activity Participant

I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

For CME questions, please contact the CME Office 410-955-2959 or email cmenet@jhmi.edu.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)


myCME privacy policy

THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT

The mission of the Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and researchlocally, nationally, and globally. Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns-please feel free to e-mail us: IJHN@.jhmi.edu.

Instructions

The following activity is an archived in-office educational session designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME/CNE/CPE post-assessment and evaluation. All 3 sections must be completed to receive CME/CNE/CPE credit. A certificate of participation will be available online immediately following successful completion of the activity.

HARDWARE & SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue